Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPAN: Safety and PK of VH3810109 + rHuPH20 in Healthy Adults
NCT05291520Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Feb 2022
- Primary completion
- Apr 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, open-label trial of VH3810109 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by ViiV Healthcare. Primary endpoints: Number of Participants With Grade 2 or Higher Adverse Events Following SC Administration at 24 weeks, Number of Participants With Serious Adverse Events Following SC Administration at 24 weeks and 5 more. Started Feb 2022; status: completed.
02
Drugs
VH3810109
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05291520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05291520.